

عنوان مقاله:

Contribution of BRCA1 and BRCA2 Germ Line Mutations to Triple Negative Breast Cancer Patients

محل انتشار:

اولین سمپوزیوم بین المللی سرطان نسترن (سال: 1394)

تعداد صفحات اصل مقاله: 1

نویسندگان:

MU Rashidi - *Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan*
German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany

N Muhammad - *Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan*

S Bajwa - *Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan*

S Gull - *Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan*

خلاصه مقاله:

Objectives: Women harboring BRCA1/2 mutations have high lifetime risks of developing breast and ovarian cancer. Current criteria for BRCA1/2 testing to identify individuals at-risk rely predominantly on family history of breast/ovarian cancer and early age of disease onset. Here we investigated if the triple-negative breast cancer (TNBC) phenotype is pertinent in identifying candidates for BRCA1/2 testing in Pakistan. **Methods:** Five hundred and twenty-three breast cancer patients including 237 diagnosed with early-onset disease (<30 years of age) and 286 with a positive family history of breast/ovarian cancer were enrolled at the SKMCH & RC from June 2001 to February 2014. All patients underwent comprehensive BRCA1/2 testing for small-range mutations and large genomic rearrangements. **Results:** Of the breast cancer patients, 36.7% (192/523) presented with TNBC. BRCA1/2 mutation screening revealed 73 mutations in this group: 71 (97.3%) in BRCA1 and two (2.7%) in BRCA2. The prevalence of BRCA1 mutations was 37.0% (71/192), which was significantly higher compared to that of non-TNBC cases (10.3% (34/331)) ($P < 0.0001$). In the subgroups of early-onset and familial breast/ovarian cancer patients BRCA1 mutations were also more common in TNBC than non-TNBC patients (14.5% (13/90) vs. 5.5% (8/147), $P=0.03$) and (56.9% (58/102) vs. 14.1% (26/184), $P < 0.0001$), respectively. TNBC patients harboring BRCA1 mutations ($n=71$) were diagnosed at later age than non-carriers ($n=119$) ($p=0.002$). **Conclusion:** The high prevalence of BRCA1 mutations in Pakistani TNBC patients with early-onset disease regardless of a family history of breast/ovarian cancer and the predominance of BRCA1 mutations suggest TNBC status to be included as a criterion for BRCA1 testing in Pakistan.

کلمات کلیدی:

لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/513623>



